{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:15:07Z","timestamp":1785784507960,"version":"3.56.0"},"reference-count":118,"publisher":"Georg Thieme Verlag KG","issue":"12","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Migraine is one of the most prevalent and disabling diseases in the world. Migraine attack treatments and prophylactic treatments of this disease are essential to lessen its individual, social, and economic impact. This is a narrative review of the main drugs used for treating migraine, as well as the experimental models and the theoretical frameworks that led to their development. Ergot derivatives, triptans, non-steroid anti-inflammatory drugs, tricyclic antidepressants, beta-blockers, flunarizine, valproic acid, topiramate, onabotulinumtoxin A, ditans, monoclonal antibodies against CGRP and its receptor, and gepants are discussed. Possible therapeutic targets for the development of new drugs that are under development are also addressed. Many of the drugs currently in use for treating migraine were developed for the treatment of other diseases, but have proven effective for the treatment of migraine, expanding knowledge about the disease. With a better understanding of the pathophysiology of migraine, new drugs have been and continue to be developed specifically for the treatment of this disease.<\/jats:p>","DOI":"10.1055\/s-0043-1777723","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:05:43Z","timestamp":1703894743000},"page":"1084-1097","source":"Crossref","is-referenced-by-count":10,"title":["The history and rationale of the development of new drugs for migraine treatment"],"prefix":"10.1055","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-7475","authenticated-orcid":false,"given":"Pedro Andr\u00e9","family":"Kowacs","sequence":"additional","affiliation":[{"name":"Instituto de Neurologia de Curitiba, Servi\u00e7o de Neurologia, Curitiba PR, Brazil."},{"name":"Universidade Federal do Paran\u00e1, Complexo Hospital de Cl\u00ednicas, Unidade do Sistema Nervoso, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-2637","authenticated-orcid":false,"given":"Pedro Augusto","family":"Sampaio Rocha-Filho","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Centro de Ci\u00eancias M\u00e9dicas, Divis\u00e3o de Neuropsiquiatria, Recife PE, Brazil."},{"name":"Universidade de Pernambuco, Hospital Universit\u00e1rio Oswaldo Cruz, Cl\u00ednica de Cefaleia, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0068-1905","authenticated-orcid":false,"given":"M\u00e1rio Fernando Prieto","family":"Peres","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Hospital das Cl\u00ednicas, Instituto de Psiquiatria, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1805-1346","authenticated-orcid":false,"given":"Lars","family":"Edvinsson","sequence":"additional","affiliation":[{"name":"Lund University, Institute of Clinical Sciences, 22185 Lund, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates","volume":"23","author":"L J Stovner","year":"2022","journal-title":"J Headache Pain"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"T J Steiner","year":"2020","journal-title":"J Headache Pain"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s10194-019-1036-6","article-title":"Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys","volume":"20","author":"M FP Peres","year":"2019","journal-title":"J Headache Pain"},{"key":"ref4","volume-title":"The \u201cBeating of Hammers\u201d: Classical and medieval approaches to hemicrania","author":"K Foxhall","year":"2019"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archneurpsyc.1938.02270040093005","article-title":"Mechanism of migraine headache and action of ergotamine tartrate","volume":"39","author":"J R Graham","year":"1938","journal-title":"Arch Neur Psych"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/jn.1944.7.6.359","article-title":"Spreading depression of activity in the cerebral cortex","volume":"7","author":"A AP Leao","year":"1944","journal-title":"J Neurophysiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/archneurpsyc.1941.02280200137007","article-title":"Patterns of cerebral integration indicated by the scotomas of migraine","volume":"46","author":"K S Lashley","year":"1941","journal-title":"Arch NeurPsych"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ana.410120510","article-title":"Persistent oligemia of rat cerebral cortex in the wake of spreading depression","volume":"12","author":"M Lauritzen","year":"1982","journal-title":"Ann Neurol"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ana.410090406","article-title":"Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine","volume":"9","author":"J Olesen","year":"1981","journal-title":"Ann Neurol"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nm0202-136","article-title":"Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model","volume":"8","author":"H Bolay","year":"2002","journal-title":"Nat Med"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nm0795-658","article-title":"Brain stem activation in spontaneous human migraine attacks","volume":"1","author":"C Weiller","year":"1995","journal-title":"Nat Med"},{"issue":"08","key":"ref12","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/head.14597","article-title":"Aura phenomena do not initiate migraine attacks-Findings from neuroimaging","volume":"63","author":"J Mehnert","year":"2023","journal-title":"Headache"},{"issue":"08","key":"ref13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/HEAD.14623","article-title":"Aura is a symptom of a migraine attack, not its cause","volume":"63","author":"A Charles","year":"2023","journal-title":"Headache"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies - successful translation from bench to clinic","volume":"14","author":"L Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11916-022-01015-z","article-title":"Premonitory and Accompanying Symptoms in Childhood Migraine","volume":"26","author":"P A Sampaio Rocha-Filho","year":"2022","journal-title":"Curr Pain Headache Rep"},{"issue":"S 02","key":"ref16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10072-020-04808-5","article-title":"Migraine neuroscience: from experimental models to target therapy","volume":"41","author":"R Greco","year":"2020","journal-title":"Neurol Sci"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.3390\/ijms20122932","article-title":"Migraine: Experimental models and novel therapeutic approaches","volume":"20","author":"G Tardiolo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/0028-3908(91)90165-8","article-title":"Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion","volume":"30","author":"M G Buzzi","year":"1991","journal-title":"Neuropharmacology"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410230214","article-title":"Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system","volume":"23","author":"P J Goadsby","year":"1988","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/brain\/119.1.249","article-title":"Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study","volume":"119","author":"K L Hoskin","year":"1996","journal-title":"Brain"},{"key":"ref21","volume-title":"Lehrbuch der Funktionellen Nervenkrankheiten.","author":"A Eulenburg","year":"1871"},{"key":"ref22","first-page":"513","volume":"52","author":"MAp Tzanck","year":"1928","journal-title":"Bull Soc M\u00e9d Hosp Paris"},{"issue":"07","key":"ref23","first-page":"467","article-title":"Treatment of the migraine attack","volume":"2","author":"A P Friedman","year":"1948","journal-title":"Am Pract Dig Treat"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000228445","article-title":"Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat's paw by serotonin","volume":"12","author":"W Doepfner","year":"1958","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000229055","article-title":"Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine","volume":"15","author":"F Sicuteri","year":"1959","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"ref26","first-page":"297","volume-title":"Ergot alkaloids in migraine: Is the effect via 5-HT receptors?","author":"E M\u00fcller-Schweinitzer","year":"1992"},{"issue":"8138","key":"ref27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(79)90343-X","article-title":"Tolfenamic acid is as effective as ergotamine during migraine attacks","volume":"2","author":"H Hakkarainen","year":"1979","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"A M Migraine","year":"2020","journal-title":"N Engl J Med"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1742-1241.1972.tb04381.x","article-title":"A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine","volume":"26","author":"G M Yuill","year":"1972","journal-title":"Br J Clin Pract"},{"issue":"03","key":"ref30","first-page":"197","article-title":"The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study","volume":"19","author":"F C Tulunay","year":"2004","journal-title":"Funct Neurol"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1526-4610.2006.00376.x","article-title":"Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study","volume":"46","author":"J Goldstein","year":"2006","journal-title":"Headache"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1476-5381.1988.tb11630.x","article-title":"GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein","volume":"94","author":"P PA Humphrey","year":"1988","journal-title":"Br J Pharmacol"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pharmthera.2012.08.011","article-title":"Basic mechanisms of migraine and its acute treatment","volume":"136","author":"L Edvinsson","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3390\/biomedicines11071864","article-title":"Serotonergic modulation of neurovascular transmission: A focus on prejunctional 5-HT receptors\/mechanisms","volume":"11","author":"A Gonz\u00e1lez-Hern\u00e1ndez","year":"2023","journal-title":"Biomedicines"},{"issue":"S 04","key":"ref35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/head.12601","article-title":"Triptans in the acute treatment of migraine: A systematic review and network meta-analysis","volume":"55","author":"C Cameron","year":"2015","journal-title":"Headache"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/pmt.13.71","article-title":"Sumatriptan iontophoretic transdermal system for the acute treatment of migraine","volume":"4","author":"M Vikelis","year":"2014","journal-title":"Pain Manag (Lond)"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/head.13424","article-title":"Safety problems with a transdermal patch for migraine: lessons from the development, approval, and marketing process","volume":"58","author":"E W Loder","year":"2018","journal-title":"Headache"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","article-title":"Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy","volume":"60","author":"P Tfelt-Hansen","year":"2000","journal-title":"Drugs"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"D L Nelson","year":"2010","journal-title":"Cephalalgia"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-022-01394-z","article-title":"Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors","volume":"23","author":"J CA Edvinsson","year":"2022","journal-title":"J Headache Pain"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","article-title":"Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study","volume":"11","author":"M F\u00e4rkkil\u00e4","year":"2012","journal-title":"Lancet Neurol"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0333102421989232","article-title":"Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study","volume":"41","author":"M Ashina","year":"2021","journal-title":"Cephalalgia"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"P J Goadsby","year":"2019","journal-title":"Brain"},{"issue":"24","key":"ref44","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study","volume":"91","author":"B Kuca","year":"2018","journal-title":"Neurology"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.clinthera.2021.04.004","article-title":"Tolerability and safety of lasmiditan treatment in elderly patients with migraine: Post hoc analyses from randomized studies","volume":"43","author":"V T Martin","year":"2021","journal-title":"Clin Ther"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials","volume":"20","author":"R E Shapiro","year":"2019","journal-title":"J Headache Pain"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/14728222.11.9.1179","article-title":"Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists","volume":"11","author":"L Edvinsson","year":"2007","journal-title":"Expert Opin Ther Targets"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/17425255.2018.1416097","article-title":"Side effects associated with current and prospective antimigraine pharmacotherapies","volume":"14","author":"A Gonz\u00e1lez-Hern\u00e1ndez","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9741","key":"ref49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(10)60323-6","article-title":"New drugs in migraine treatment and prophylaxis: telcagepant and topiramate","volume":"376","author":"L Edvinsson","year":"2010","journal-title":"Lancet"},{"issue":"09","key":"ref50","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/head.14389","article-title":"Zavegepant nasal spray for the acute treatment of migraine: A Phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial","volume":"62","author":"R Croop","year":"2022","journal-title":"Headache"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, tolerability, and efficacy of zavegepant 10\u2009mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial","volume":"22","author":"R B Lipton","year":"2023","journal-title":"Lancet Neurol"},{"issue":"23","key":"ref52","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"D W Dodick","year":"2019","journal-title":"N Engl J Med"},{"issue":"01","key":"ref53","first-page":"45","article-title":"The migraine syndrome","volume":"44","author":"A P Friedman","year":"1968","journal-title":"Bull N Y Acad Med"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/archneur.1979.00500470065013","article-title":"Amitriptyline in migraine prophylaxis","volume":"36","author":"J R Couch","year":"1979","journal-title":"Arch Neurol"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1468-1331.2009.02631.x","article-title":"Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors","volume":"16","author":"C Lampl","year":"2009","journal-title":"Eur J Neurol"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0002-9149(66)90056-7","article-title":"The prophylactic value of propranolol in angina pectoris","volume":"18","author":"R Rabkin","year":"1966","journal-title":"Am J Cardiol"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.22.4.366","article-title":"The treatment of migraine with propranolol","volume":"22","author":"R B Weber","year":"1972","journal-title":"Neurology"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1600-0404.1986.tb07873.x","article-title":"The difference between non-selective and beta 1-selective beta-blockers in their effect on platelet function in migraine patients","volume":"74","author":"C Hedman","year":"1986","journal-title":"Acta Neurol Scand"},{"issue":"09","key":"ref60","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/archneur.1997.00550210071015","article-title":"A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura","volume":"54","author":"R G Kaniecki","year":"1997","journal-title":"Arch Neurol"},{"key":"ref61","first-page":"1870","article-title":"[Results of treatment of migraine patients with cinnarizine and flunarizine]","volume":"31","author":"C Drillisch","year":"1980","journal-title":"Med Welt"},{"issue":"06","key":"ref62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1526-4610.1981.hed2106235.x","article-title":"A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine","volume":"21","author":"P Louis","year":"1981","journal-title":"Headache"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0404.1988.tb03667.x","article-title":"Valproate: a new drug in migraine prophylaxis","volume":"78","author":"K V S\u00f8rensen","year":"1988","journal-title":"Acta Neurol Scand"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1468-2982.1992.1202081.x","article-title":"Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo","volume":"12","author":"R Hering","year":"1992","journal-title":"Cephalalgia"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"S D Silberstein","year":"2007","journal-title":"Headache"},{"issue":"07","key":"ref66","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"H C Diener","year":"2007","journal-title":"Cephalalgia"},{"issue":"08","key":"ref67","first-page":"943","article-title":"Topiramate in migraine prophylaxis\u2013results from a placebo-controlled trial with propranolol as an active control","volume":"251","author":"H-C Diener","year":"2004","journal-title":"J Neurol"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0333102410372427","article-title":"Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study","volume":"31","author":"R B Lipton","year":"2011","journal-title":"Cephalalgia"},{"issue":"10","key":"ref69","doi-asserted-by":"crossref","first-page":"e2290","DOI":"10.1002\/brb3.2290","article-title":"Advances in topiramate as prophylactic treatment for migraine","volume":"11","author":"C Hu","year":"2021","journal-title":"Brain Behav"},{"issue":"02","key":"ref70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","article-title":"Botulinum toxin injections for cervical dystonia","volume":"40","author":"J Jankovic","year":"1990","journal-title":"Neurology"},{"issue":"08","key":"ref71","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14656566.7.8.1085","article-title":"Botulinum toxin type A for the treatment of migraine","volume":"7","author":"S Aurora","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"06","key":"ref72","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"D W Dodick","year":"2010","journal-title":"Headache"},{"issue":"S 01","key":"ref73","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.parkreldis.2011.06.013","article-title":"Updates on the antinociceptive mechanism hypothesis of botulinum toxin A","volume":"17","author":"K R Aoki","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"08","key":"ref74","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-0042-1756441","article-title":"Consensus of the Brazilian Headache Society (SBCe) for the prophylactic treatment of episodic migraine: Part I","volume":"80","author":"E M Melhado","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"issue":"09","key":"ref75","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1055\/s-0042-1755320","article-title":"Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II","volume":"80","author":"P SF Santos","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40259-017-0250-5","article-title":"CGRP monoclonal antibodies for migraine: Rationale and progress","volume":"31","author":"H Yuan","year":"2017","journal-title":"BioDrugs"},{"issue":"01","key":"ref77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","article-title":"Erenumab in highly therapy-refractory migraine patients: First German real-world evidence","volume":"21","author":"A Scheffler","year":"2020","journal-title":"J Headache Pain"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"D W Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"22","key":"ref79","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"P J Goadsby","year":"2017","journal-title":"N Engl J Med"},{"issue":"06","key":"ref80","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"S Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"20","key":"ref81","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial","volume":"92","author":"S J Tepper","year":"2019","journal-title":"Neurology"},{"issue":"24","key":"ref82","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"H C Detke","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"ref83","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"W M Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"issue":"03","key":"ref84","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0333102420966658","article-title":"Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine","volume":"41","author":"D W Dodick","year":"2021","journal-title":"Cephalalgia"},{"issue":"08","key":"ref85","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"V Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"09","key":"ref86","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial","volume":"75","author":"V L Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"issue":"11","key":"ref87","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial","volume":"13","author":"D W Dodick","year":"2014","journal-title":"Lancet Neurol"},{"issue":"19","key":"ref88","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial","volume":"319","author":"D W Dodick","year":"2018","journal-title":"JAMA"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"M D Ferrari","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"ref90","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"S D Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study","volume":"21","author":"S D Silberstein","year":"2020","journal-title":"J Headache Pain"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1220285","DOI":"10.3389\/fneur.2023.1220285","article-title":"Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan","volume":"14","author":"S Suzuki","year":"2023","journal-title":"Front Neurol"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"M Ashina","year":"2020","journal-title":"Cephalalgia"},{"issue":"07","key":"ref94","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"21","author":"M Ashina","year":"2022","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/head.14036","article-title":"Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2","volume":"61","author":"H C Diener","year":"2021","journal-title":"Headache"},{"issue":"13","key":"ref96","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"R B Lipton","year":"2020","journal-title":"Neurology"},{"issue":"09","key":"ref97","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","article-title":"Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"D W Dodick","year":"2014","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref98","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0333102420973994","article-title":"Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension","volume":"41","author":"R B Lipton","year":"2021","journal-title":"Cephalalgia"},{"issue":"10","key":"ref99","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/head.13997","article-title":"Reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: Post hoc analysis from HALO CM Study","volume":"60","author":"R B Lipton","year":"2020","journal-title":"Headache"},{"issue":"07","key":"ref100","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/0333102421989601","article-title":"Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis","volume":"41","author":"K Drellia","year":"2021","journal-title":"Cephalalgia"},{"issue":"08","key":"ref101","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"J Ailani","year":"2021","journal-title":"N Engl J Med"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"R Croop","year":"2019","journal-title":"Lancet"},{"issue":"02","key":"ref103","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12325-022-02369-x","article-title":"Health state utility mapping of rimegepant for the preventive treatment of migraine: Double-blind treatment phase and open label extension (BHV3000-305)","volume":"40","author":"L C Powell","year":"2023","journal-title":"Adv Ther"},{"issue":"03","key":"ref104","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/head.14433","article-title":"Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine","volume":"63","author":"A M Blumenfeld","year":"2023","journal-title":"Headache"},{"issue":"01","key":"ref105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/head.14439","article-title":"Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial","volume":"63","author":"M Ashina","year":"2023","journal-title":"Headache"},{"issue":"04","key":"ref106","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/pmt-2021-0073","article-title":"Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial","volume":"12","author":"R Boinpally","year":"2022","journal-title":"Pain Manag (Lond)"},{"issue":"06","key":"ref107","doi-asserted-by":"crossref","first-page":"e2215499","DOI":"10.1001\/jamanetworkopen.2022.15499","article-title":"Rates of response to atogepant for migraine prophylaxis among adults: A secondary analysis of a randomized clinical trial","volume":"5","author":"R B Lipton","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"08","key":"ref108","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1212\/WNL.0000000000201568","article-title":"Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the randomized, double-blind, phase 3 ADVANCE Trial","volume":"100","author":"R B Lipton","year":"2023","journal-title":"Neurology"},{"issue":"01","key":"ref109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/03331024211042385","article-title":"Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial","volume":"42","author":"T J Schwedt","year":"2022","journal-title":"Cephalalgia"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"P Pozo-Rosich","year":"2023","journal-title":"Lancet"},{"issue":"01","key":"ref111","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-023-01567-4","article-title":"Future targets for migraine treatment beyond CGRP","volume":"24","author":"L Al-Hassany","year":"2023","journal-title":"J Headache Pain"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuropharm.2019.02.015","article-title":"Mechanosensitive meningeal nociception via Piezo channels: Implications for pulsatile pain in migraine?","volume":"149","author":"N Mikhailov","year":"2019","journal-title":"Neuropharmacology"},{"issue":"08","key":"ref113","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1517\/13543784.2014.918953","article-title":"Drugs targeting nitric oxide synthase for migraine treatment","volume":"23","author":"P Barbanti","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0333102420970889","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention","volume":"41","author":"M Ashina","year":"2021","journal-title":"Cephalalgia"},{"issue":"01","key":"ref115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s10194-018-0852-4","article-title":"PACAP and its role in primary headaches","volume":"19","author":"L Edvinsson","year":"2018","journal-title":"J Headache Pain"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuroscience.2018.10.004","article-title":"Expression of pituitary adenylate cyclase-activating peptide, calcitonin gene-related peptide and headache targets in the trigeminal ganglia of rats and humans","volume":"393","author":"S D Frederiksen","year":"2018","journal-title":"Neuroscience"},{"issue":"12","key":"ref117","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1177\/0333102420929026","article-title":"Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system","volume":"40","author":"J CA Edvinsson","year":"2020","journal-title":"Cephalalgia"},{"issue":"06","key":"ref118","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0333102419893962","article-title":"Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions","volume":"40","author":"K Warfvinge","year":"2020","journal-title":"Cephalalgia"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fphys.2014.00078","article-title":"Involvement of gap junction channels in the pathophysiology of migraine with aura","volume":"5","author":"D Sarrouilhe","year":"2014","journal-title":"Front Physiol"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1777723.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:07:20Z","timestamp":1703894840000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1777723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":118,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,29]]},"published-print":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1777723","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}